Table 2.
Univariate analysis of baseline data related to myelosuppression
| Variable | Total | Myelosuppression Group (n=391) | Non-Myelosuppression Group (n=193) | Statistic | P-value |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 308 (78.77%) | 229 (81.79%) | 79 (71.17%) | 5.356 | 0.021 |
| Female | 83 (21.23%) | 51 (18.21%) | 32 (28.83%) | ||
| Treatment Regimen | |||||
| Docetaxel + Platinum | 119 (30.43%) | 79 (28.21%) | 40 (36.04%) | 14.310 | 0.003 |
| Gemcitabine + Platinum | 75 (19.18%) | 66 (23.57%) | 9 (8.11%) | ||
| Pemetrexed + Platinum | 107 (27.37%) | 69 (24.64%) | 38 (34.23%) | ||
| Others | 90 (23.02%) | 66 (23.57%) | 24 (21.62%) | 14.310 | 0.003 |
| Targeted Therapy | |||||
| Yes | 48 (12.28%) | 42 (15.00%) | 6 (5.41%) | 6.795 | 0.009 |
| No | 343 (87.72%) | 238 (85.00%) | 105 (94.59%) | ||
| First Chemotherapy | |||||
| Yes | 210 (53.71%) | 162 (57.86%) | 48 (43.24%) | 6.828 | 0.009 |
| No | 181 (46.29%) | 118 (42.14%) | 63 (56.76%) | ||
| Age (years) | 62.95±7.73 | 63.35±7.30 | 61.95±8.69 | 1.622 | 0.106 |
| BMI (kg/m2) | 22.24±3.00 | 21.84±2.99 | 23.23±2.79 | 4.216 | <0.001 |
| White Blood Cell Count (109/L) | 6.41±2.49 | 6.00±2.28 | 7.46±2.69 | 5.406 | <0.001 |
| Neutrophil Count (109/L) | 4.19±1.93 | 4.00±1.76 | 4.67±2.25 | 3.123 | 0.002 |
| Hemoglobin (g/L) | 124.09±17.64 | 125.29±17.43 | 121.08±17.87 | 2.135 | 0.033 |
| Platelet Count (109/L) | 228.27±82.23 | 220.26±80.94 | 248.46±82.38 | 3.091 | 0.002 |
| Total Protein (g/L) | 67.10±6.32 | 66.78±6.29 | 67.91±6.36 | 1.604 | 0.109 |
Note: BMI = Body Mass Index; “Others” in Treatment Regimen includes etoposide + platinum and paclitaxel + platinum.